What might CSL shares be faced with in November?

Time to saddle up for the second last month of the year. Here's a peek at the points of interest for CSL in November.

| More on:

Should you invest $1,000 in Ishares Core S&p/asx 200 Etf right now?

Before you buy Ishares Core S&p/asx 200 Etf shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Ishares Core S&p/asx 200 Etf wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new month is underway for CSL Limited (ASX: CSL) shares today after an abysmal October for the biotech heavyweight. At the end of yesterday, Australia's third most valuable listed company tallied up a monthly share price decline of 7.4%, settling at $232.35.

The tenth month of 2023 was unkind to other ASX healthcare shares (and markets more broadly) as well, with stalwarts, such as Cochlear Limited (ASX: COH) and Sonic Healthcare Ltd (ASX: SHL), suffering decreases in share price.

In any event, CSL shares were tenderised last month, arguably led by speculation around weight-loss drugs. The question is then: what could be awaiting shareholders this month?

The month ahead for CSL shares

For those CSL investors who can appreciate quieter times, you could be in luck.

The past few months have been almost non-stop action at the plasma medical products company.

In August, investors were supplied with the latest full-year results. Then, CSL shares went ex-dividend in September. Finally, October gave rise to the fluster from new research showing possible uses of semaglutide in chronic kidney disease — as well as capital markets day to boot.

In contrast, the November schedule is entirely uneventful. No dividend dates, no annual general meeting, and no quarterly results. Does that mean we won't hear a peep from anyone about CSL shares? Maybe… though, it is unlikely.

It's fair to say that weight-loss drugs have the investing world captivated. Every person and their dog are vigorously trying to establish the next area of disruption caused by GLP-1 receptor agonists, such as Ozempic.

Findings of a safety review conducted by the European Medicines Agency (EMA) into GLP-1s are expected this month. The medical body has decided to see whether there is any causal relationship following a number of reports of "suicidal thoughts and self-injury" among people taking the medicine.

Notably, the EMA determined on 27 October 2023 that there was no supporting link between GLP-1 drugs and thyroid cancer. The review was prompted by a publication in 2022 suggesting a possible increased risk among people taking GLP-1 agonists for type 2 diabetes.

There's a good chance investors will be on the lookout for information relating to the drug's application in medical areas where CSL operates.

Beyond this month

Looking further out than November, a handful of analysts expect upside to CSL shares.

Now trading on a price-to-earnings (P/E) ratio of around 33 times, is the biotech company 'cheap'? Marcus Today analyst Matt Lattin considers it a buy, referencing improving gross margins and a diverse strategy.

CSL expects to grow its net profit after tax (NPAT) by between 13% to 17% in FY2024. At the midpoint, this would value CSL shares at approximately 24 times FY24 earnings.

Motley Fool contributor Mitchell Lawler has positions in Sonic Healthcare. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL, Cochlear, and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Telix share price jumps 13% on FY24 profit surge

This pharma stock has delivered another stunning result. Here's what it reported.

Read more »

Health professional working on his laptop.
Earnings Results

2 ASX 300 healthcare shares making big moves on earnings updates

Let's see what these two shares reported on Thursday.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

2 ASX 200 pharmaceutical shares surging on big US news

Big news is getting investors excited on Wednesday. Let's find out what is happening.

Read more »

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »